Wigginton, Jon M.
Beth Israel Deaconess Medical Center · Yale New Haven Hospital · Johns Hopkins University · Johns Hopkins Medicine · Yale Cancer Center · Yale University · Massachusetts General Hospital · Bristol-Myers Squibb (United States) · Dana-Farber Cancer Institute · Sidney Kimmel Comprehensive Cancer Center · Smilow Cancer Hospital
4 papers on CoChat
Most cited papers
- Verified
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 12,628
- Verified
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 7,945
- Verified
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 4,230
- Verified
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 2,222
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free